Esketamine vs. Off-Label Ketamine: U.S. Regulatory Divide Deepens

FDA Approval of Esketamine and the Off-Label Ketamine Landscape

Esketamine, marketed as Spravato and approved by the U.S. Food and Drug Administration (FDA) in 2019 for treatment-resistant depression, is the only ketamine-based medication with formal regulatory clearance for psychiatric use. In contrast, racemic ketamine—an older anesthetic agent—remains widely prescribed off-label for depression and other mental health conditions, despite lacking FDA approval for these indications. This regulatory divide has created a complex environment for clinicians and patients, with esketamine subject to strict Risk Evaluation and Mitigation Strategy (REMS) controls and off-label ketamine operating in a patchwork of state and institutional policies.

Off-label use refers to the prescription of an approved drug for an unapproved indication or in an unapproved manner. While legal under federal law, off-label ketamine for mental health is not subject to the same clinical trial evidence or post-marketing surveillance as esketamine, leading to divergent standards of care and uncertainty for practitioners.

Mechanisms Driving the Regulatory Gap

The regulatory gap between esketamine and off-label ketamine arises from differences in approval pathways, clinical evidence, and risk management requirements. Esketamine underwent rigorous Phase 3 trials (e.g., TRANSFORM-1, TRANSFORM-2; see FDA Spravato approval), demonstrating efficacy and safety for treatment-resistant depression. This led to its approval with REMS restrictions, requiring administration in certified healthcare settings and monitoring for dissociation and abuse potential.

Racemic ketamine, in contrast, is FDA-approved only as an anesthetic, with its antidepressant effects supported by smaller studies and real-world evidence rather than large-scale, FDA-reviewed trials. The lack of formal regulatory oversight means that dosing protocols, monitoring, and patient selection criteria vary widely across clinics, increasing the risk of inconsistent outcomes and adverse events. Notably, this regulatory ambiguity has allowed a proliferation of ketamine clinics, some of which operate with minimal psychiatric oversight—a failure mode rarely discussed in mainstream coverage.

Policy, Legal, and Insurance Implications

The regulatory gap has significant policy and legal implications for clinicians and operators. Esketamine's FDA approval and REMS program provide a clear legal framework and a pathway for insurance reimbursement, though coverage remains inconsistent. Off-label ketamine, by contrast, is typically not covered by insurance, placing the financial burden on patients and raising equity concerns. The lack of federal guidance on best practices for off-label use exposes clinicians to potential liability, especially if adverse events occur or if state boards scrutinize prescribing practices.

From a research standpoint, the divide complicates data collection and comparative effectiveness studies. While esketamine's use is tracked through the REMS system, off-label ketamine lacks centralized reporting, hindering efforts to systematically assess long-term safety and efficacy. This fragmentation also affects the development of clinical guidelines, as professional societies must navigate a landscape where evidence quality and regulatory status diverge.

Risks, Unknowns, and the Need for Federal Guidance

The primary risks associated with the current regulatory environment include inconsistent patient safety standards, variable clinical outcomes, and legal exposure for providers. Adverse events such as dissociation, hypertension, and potential for misuse are well-documented for both esketamine and racemic ketamine, but the absence of standardized protocols for off-label use heightens these risks. Moreover, the lack of insurance coverage for off-label ketamine can incentivize cost-cutting measures, such as reduced monitoring or inadequate follow-up, that may compromise patient safety.

One underappreciated risk is the potential for regulatory backlash if high-profile adverse events occur in the off-label setting, which could trigger state-level restrictions or federal intervention. This scenario would have significant implications for both clinical practice and ongoing research, underscoring the urgent need for clearer federal guidance on off-label psychedelic therapies.

Looking Ahead: Bridging the Divide

Bridging the regulatory divide between esketamine and off-label ketamine will require coordinated action from federal agencies, professional societies, and industry stakeholders. Potential solutions include the development of national clinical guidelines, expanded post-marketing surveillance for off-label use, and targeted research funding to support large-scale trials of racemic ketamine. The FDA could also consider issuing guidance on best practices for off-label psychedelic therapies, as it has done in other therapeutic areas.

For now, clinicians and operators must navigate a landscape marked by uncertainty, balancing patient demand with evolving standards of care and legal risk. The next two years will likely see increased scrutiny of ketamine clinics, greater calls for regulatory harmonization, and continued debate over the role of off-label use in the broader psychedelic renaissance.

Byline: Written by Dr. Alex Morgan, MD, MPH. Reviewed by Dr. Lisa Harding, MD, on 2026-10-04. Research based on direct review of FDA regulatory documents, clinical trial registries, and official manufacturer statements.